Pfizer, Inc. has announced that they are ceasing global development and commercialization of Beqvez™, the company’s hemophilia B gene therapy product.
Pfizer, Inc. has announced that they are ceasing global development and commercialization of Beqvez™, the company’s hemophilia B gene therapy product.